Date: 2025/03/20 - 00:00
The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now that the GLP-1 drug shortage has ended. People who rely on compounded GLP-1s say they may not be able to afford brand-name versions, which are often not covered by insurance.
Date: 2025/01/22 - 00:32
A large study published in Nature Medicine reviewed the effects of GLP-1 drugs like Ozempic and Mounjaro on 175 different health outcomes. The findings show benefits for brain and heart health, but risks of developing gastrointestinal, kidney, and pancreatic issues.